Form 8-K Eton Pharmaceuticals, For: May 28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

May 28, 2021

Date of Report (Date of earliest event reported)

 

 

ETON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware		001-38738		37-1858472
(State		(Commission		(I.R.S. Employer
of incorporation)		File Number)		Identification Number)

 

21925 W. Field Parkway, Suite 235

Deer Park, Illinois 60010-7278

(Address of principal executive offices) (Zip code)

 

(847) 787-7361

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ETON		NASDAQ Global Market

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

 

 

 

Item 8.01 Other Events.

 

On May 28, 2021, Eton Pharmaceuticals, Inc. (the “company”) received an update on the zonisamide oral suspension project, which the company previously sold to Azurity Pharmaceuticals. Eton was notified that its partner received a Complete Response Letter(“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the New Drug Application for zonisamide oral suspension. The only deficiencies listed in the CRL were related to the Facility Inspections section. The inspection of the third-party manufacturing facility was unable to occur due to travel restrictions. The FDA did not provide a timeline for the inspection but stated that it intends to inspect the facility once travel restrictions are lifted. Eton’s partner is responsible for all regulatory activities and will remain in communication with the FDA. Pursuant to terms of the sale, Eton is entitled to milestone payments and royalties on future sales of the product.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 28, 2021	By:	/s/ W. Wilson Troutman
		W. Wilson Troutman
		Chief Financial Officer and Secretary
		(Principal Financial Officer)

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Eton Pharmaceuticals Inc. (ETON) Enters Share and Warrant Sale Agreements
• Electrolit Renews Partnership with Patricio "Pato" O'Ward, Extending Sponsorship for Third Consecutive Year
• Nokia Corporation: Repurchase of own shares on 19.04.2024